Hot Features
プレミアム
Genmab AS (GE9)
TG
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | Mr. Michael KavanaghSenior Director, Head of Strategic Engagement & Oncology Marketing and Non-Independent Director | -526.00 | 142.55k | 売り | 271.00 | 0.00 | -100.00% |
| 2026-04-01 | Dr. Judith V. KlimovskyExec. VP & Chief Development Officer | 4.74k | 1.30M | Derivative Exercise and Retained Stock | 273.16 | 15.56k | 43.86% |
| 2026-04-01 | Dr. Tahamtan AhmadiExec. VP, Chief Medical Officer & Head of Experimental Medicines | 5.19k | 1.42M | Derivative Exercise and Retained Stock | 273.16 | 10.05k | 106.66% |
| 2026-04-01 | Mr. Anthony PaganoExec. VP & CFO | 4.21k | 1.15M | Derivative Exercise and Retained Stock | 273.16 | 10.31k | 68.89% |
| 2026-04-01 | Dr. Jan G.J. van de WinkelCo-Founder, President & CEO | 439.00 | 119.92k | Derivative Exercise and Retained Stock | 273.16 | 659.94k | 0.07% |
| 2026-03-02 | Dr. Jan G.J. van de WinkelCo-Founder, President & CEO | 567.00 | 0.00 | Derivative Exercise and Retained Stock | - | 659.50k | 0.09% |
| 2026-03-02 | Mr. Anthony PaganoExec. VP & CFO | 200.00 | 0.00 | Derivative Exercise and Retained Stock | - | 6.11k | 3.39% |
| 2026-03-02 | Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director | 197.00 | 0.00 | Derivative Exercise and Retained Stock | - | 865.00 | 29.49% |
| 2026-03-02 | Dr. Mijke ZachariasseVP, Head of Antibody Research Materials & Director | 64.00 | 0.00 | Derivative Exercise and Retained Stock | - | 851.00 | 8.13% |
| 2026-03-02 | Mr. Michael KavanaghSenior Director, Head of Strategic Engagement & Oncology Marketing and Non-Independent Director | 305.00 | 0.00 | Derivative Exercise and Retained Stock | - | 526.00 | 138.01% |
| 2026-02-19 | Mr. Anthony PaganoExec. VP & CFO | -1.10k | 313.50k | 売り | 285.00 | 5.91k | -15.70% |
| 2025-12-01 | Dr. Anders Gersel PedersenNon-Independent Director | 189.00 | 60.10 | Derivative Exercise and Retained Stock | 0.32 | 7.71k | 2.51% |
| 2025-12-01 | Ms. Elizabeth G. O'FarrellIndependent Director | 189.00 | 60.10 | Derivative Exercise and Retained Stock | 0.32 | 1.89k | 11.14% |
| 2025-12-01 | Ms. Deirdre P. ConnellyIndependent Chairman of the Board | 378.00 | 120.19 | Derivative Exercise and Retained Stock | 0.32 | 6.58k | 6.09% |
| 2025-12-01 | Mr. Rolf Karl-Heinz HoffmannIndependent Director | 189.00 | 60.10 | Derivative Exercise and Retained Stock | 0.32 | 3.78k | 5.26% |
| 2025-12-01 | Ms. Pernille ErenbjergIndependent Deputy Chairman | 283.00 | 89.98 | Derivative Exercise and Retained Stock | 0.32 | 5.47k | 5.46% |
| 2025-12-01 | Dr. Paolo PaolettiIndependent Director | 189.00 | 60.10 | Derivative Exercise and Retained Stock | 0.32 | 2.51k | 8.16% |
| 2025-12-01 | Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director | 189.00 | 60.10 | Derivative Exercise and Retained Stock | 0.32 | 400.00 | 89.57% |
| 2025-12-01 | Dr. Mijke ZachariasseVP, Head of Antibody Research Materials & Director | 189.00 | 60.10 | Derivative Exercise and Retained Stock | 0.32 | 690.00 | 37.72% |
| 2025-11-19 | Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director | -175.00 | 52.99k | 売り | 302.78 | 211.00 | -45.34% |
| 2025-09-09 | Dr. Jan G.J. van de WinkelCo-Founder, President & CEO | 23.27k | 3.75M | Derivative Exercise and Retained Stock | 160.99 | 658.93k | 3.66% |
| 2025-06-17 | Dr. Mijke ZachariasseVP, Head of Antibody Research Materials & Director | -250.00 | 57.34k | 売り | 229.37 | 501.00 | -33.29% |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
